12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DNX-2401: Phase I started

DNAtrix began an open-label, Spanish Phase I trial to evaluate DNX-2401 injected into the brain about 14 days before 2 cycles of oral temozolomide in about...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >